Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/28302| Наслов: | Once-weekly subcutaneous semaglutide use I GLP-1 naïve patients with type 2 diabetes in North Macedonia: real world data from the MIRAGE study. | Authors: | Milenkovikj, Tatjana Jovanovska Mishevska, Sasha Bitoska Mileva, Iskra Ahmeti, Irfan Chekorova Mitreva, Biljana |
Issue Date: | апр-2023 | Conference: | Congress of the Central European Diabetes Association (CEDA) | Abstract: | Safety and efficacy of once weekly (OW) subcutaneous (s.c.) semaglutide in T2D patients has been established in phase 3 clinical trials. In North Macedonia, no real-world evidence studies were conducted so far to assess the use of once weekly (OW) semaglutide in routine clinical practice. | URI: | http://hdl.handle.net/20.500.12188/28302 |
| Appears in Collections: | Faculty of Medicine: Conference papers |
Files in This Item:
| File | Опис | Size | Format | |
|---|---|---|---|---|
| OP 2 Abstracts_engl_CEDA_congress_2023.pdf | 1.82 MB | Adobe PDF | View/Open |
Page view(s)
48
checked on 22.9.2024
Download(s)
154
checked on 22.9.2024
Google ScholarTM
Проверете
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.